India, March 15 -- Zentalis Pharmaceuticals Inc. (ZNTL) announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer or PROC in an oral presentation at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women's Cancer.
DENALI Part 1b is a Phase 2 single-arm study that evaluated azenosertib monotherapy at the 400mg QD 5:2 dose (once daily, five days on, two days off) in patients with PROC.
As of the January 13, 2025 data cutoff, patients with Cyclin E1+ PROC tumors who were response-evaluable (patients who had at least one scan after receiving azenosertib) demonstrated an ORR of 34.9%. In the intent-to-treat patients with Cyclin E1+ PROC (p...